Publications by authors named "Nathan Comeaux"
Article Synopsis
- - BMS-986156 is a new treatment that enhances T-cell activation and, when combined with other therapies like ipilimumab and nivolumab, shows promise in controlling tumors in advanced solid cancers.
- - The study enrolled 50 patients with stage IV cancers resistant to standard treatments, dividing them into three groups receiving varying combinations of BMS-986156, ipilimumab, or nivolumab, with and without stereotactic ablative radiotherapy (SABR).
- - Results indicated that the combination therapies were generally well tolerated, though 44% of patients experienced treatment-related adverse events, with 12% having more severe events, such as increased liver enzyme levels.
Purpose: Ipilimumab plus stereotactic ablative radiotherapy (SABR) demonstrate satisfactory short-term clinical benefit and low toxicities in metastatic cancers. Here, we report the 5-year overall survival (OS) rates for patients with metastatic disease treated with this combined-modality therapy in a phase II trial (NCT02239900).
Methods And Materials: SABR was delivered to patients with metastatic lesions in the liver and lung either during the first dose (concurrent) or 1 week after the second dose (sequential) of ipilimumab (every 3 weeks for 4 cycles).
Aim: To report early findings from a phase II trial of high-dose radiotherapy (HD-RT) with or without low-dose RT (LD-RT) for metastatic cancer.
Methods: Eligible patients had metastatic disease that progressed on immunotherapy within 6 months. Patients were given either HD-RT (20-70 Gy total; 3-12.
Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.
View Article and Find Full Text PDFArticle Synopsis
- - The study addresses the challenges of cancer treatment, particularly the resistance of tumors to checkpoint inhibitors, and introduces a novel combined approach using low-dose radiotherapy (XRT) alongside immunotherapy to enhance treatment effectiveness.
- - Researchers tested this combination on mice with lung adenocarcinoma, revealing that high-dose XRT helps prepare T cells in primary tumors, while low-dose XRT allows for better immune responses in secondary tumors by modifying the tumor environment.
- - Results showed that low-dose XRT boosts the effectiveness of immune cells, such as M1 macrophages and NK cells, and reduces inhibitory factors like TGF-β, with the lack of certain immune cells negating the treatment's benefits, suggesting a promising strategy for improving
Background: Radiotherapy might augment systemic antitumoral responses to immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-small-cell lung cancer were randomly allocated immunotherapy (pembrolizumab) with or without radiotherapy. When the trials were analysed individually, a potential benefit was noted in the combination treatment arm.
View Article and Find Full Text PDFBackground: In this phase I/II trial, we evaluated the safety and effectiveness of pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from metastatic non-small cell lung cancer (mNSCLC).
Methods: Patients with lung or liver lesions amenable to RT plus at least one additional non-contiguous lesion were included regardless of programmed death-ligand 1 (PD-L1) status. Pembrolizumab was given at 200 mg every 3 weeks for up to 32 cycles with or without concurrent RT.
Introduction: Few advancements in treating limited-stage SCLC (LS-SCLC) have been made in decades. We report here a phase 1/2 trial of concurrent chemoradiotherapy (CRT) and pembrolizumab.
Methods: This single-center, open-label phase 1/2 study recruited adults with LS-SCLC or other neuroendocrine tumors and good performance status (Eastern Cooperative Oncology Group ≤ 2).